Cargando…

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review

Recent cell-based and animal experiments have demonstrated an effective reduction in botulinum neurotoxin A (BoNT/A) by copper. Aim: We aimed to analyze whether the successful symptomatic BoNT/A treatment of patients with Wilson’s disease (WD) corresponds with unusually high doses per session. Among...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hefter, Harald, Samadzadeh, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065630/ https://www.ncbi.nlm.nih.gov/pubmed/33805281 http://dx.doi.org/10.3390/toxins13040241

Ejemplares similares

The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication
por: Hefter, Harald, et al.
Publicado: (2022)

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
por: Samadzadeh, Sara, et al.
Publicado: (2020)

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson’s Disease: A Controlled Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Analysis of Running in Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2021)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
por: Hefter, Harald, et al.
Publicado: (2023)

Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson’s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
por: Hefter, Harald, et al.
Publicado: (2020)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
por: Hefter, Harald, et al.
Publicado: (2021)

Zebrafish Sensitivity to Botulinum Neurotoxins
por: Chatla, Kamalakar, et al.
Publicado: (2016)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
por: Hefter, Harald, et al.
Publicado: (2021)

Neurologic uses of botulinum neurotoxin type A
por: Ney, John P, et al.
Publicado: (2007)

Botulinum Neurotoxin Type A in Neurology: Update
por: Orsini, Marco, et al.
Publicado: (2015)

Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report
por: Hefter, Harald, et al.
Publicado: (2021)

The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2022)

Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease
por: Hefter, Harald, et al.
Publicado: (2022)

Cholinesterase Deficiency Syndrome—A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson’s Disease
por: Arslan, Max, et al.
Publicado: (2022)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
por: Hefter, Harald, et al.
Publicado: (2020)

Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
por: Hefter, Harald, et al.
Publicado: (2023)

Botulinum Neurotoxins and Cancer—A Review of the Literature
por: Mittal, Shivam O., et al.
Publicado: (2020)

Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
por: Schaefer, Sara M., et al.
Publicado: (2015)

On Botulinum Neurotoxin Variability
por: Montecucco, Cesare, et al.
Publicado: (2015)

Botulinum Neurotoxin for the Treatment of Neuropathic Pain
por: Egeo, Gabriella, et al.
Publicado: (2020)

The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2020)

Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?
por: Poulain, Bernard, et al.
Publicado: (2019)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Primary resistance of human patients to botulinum neurotoxins A and B
por: Pirazzini, Marco, et al.
Publicado: (2018)

Use of Botulinum Neurotoxin in Ophthalmology
por: Başar, Emel, et al.
Publicado: (2016)

Antipruritic Effects of Botulinum Neurotoxins
por: Gazerani, Parisa
Publicado: (2018)

Therapy of Sialorrhea with Botulinum Neurotoxin
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Botulinum neurotoxins: Future innovations
por: Brideau-Andersen, Amy, et al.
Publicado: (2023)

Conjugative Botulinum Neurotoxin-Encoding Plasmids in Clostridium botulinum
por: Marshall, Kristin M., et al.
Publicado: (2010)

Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia
por: Heyes, Richard, et al.
Publicado: (2023)

New botulinum neurotoxin constructs for treatment of chronic pain
por: Leese, Charlotte, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tfakq18c45ua2cp4k7u16tgb02